Insulin resistance and macrovascular disease

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 346-354

  Hsueh, Willa ^a   Law, Ronald E ^a   Saad, Mohammed ^a   Dy, Jacqueline ^a   Feener, Edward ^b   King, George ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000226537     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00010     Document Type: Article

References (79)

1. Welborn TA, Wearne K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979, 2:154-160.
2. Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131-141.
3. Cucimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980, 19:205-210.
4. Zavaroni I, Bonora E, Pagliara M, D All'Aglio E, Luchetti L, Buonanno G, Bonati PA, Bergonzani M, Gnudi L, Pasaari M, Reaven G: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989, 320:702-706.
5. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents. Further evidence from the Whitehall study. Diabetologia 1988, 31:737-740.
6. Reaven GM, Chen YDI, Jeppesen J, Majeux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993, 92:141-146.
7. Juhan-Vague I, Alessi MC, Vague P: Increased plasma plasminogen activator inhibitor I levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34:457-462.
8. Wingard DL, Barrett-Connor EL, Ferara A: Is insulin really a heart disease risk factor? Diabetes Care 1995, 18:1299-1304. This excellent review of epidemiologic data suggests that insulin itself may not be a risk factor for CAD.
9. Cullen K, Stenhouse NS, Wearne KL, Welborn TA: Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia: 13 year study. J Chronic Dis 1983, 36:371-377.
10. Pyorala K, Savolaninen E, Kaukola S, Pappakoski J: Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinskl Policemen Study Population. Acta Med Scand 1985, 701(suppl):38-52.
11. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991, 34:356-361.
12. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G: Hyperinsulinemia is not a major coronary risk factor in elderly men: the study of men born in 1913. Diabetologia 1992, 35:766-770.
13. Yarnell JWG, Sweetnam PM, Marks V, Teale JD, Bolton CH: Insulin in ischemic heart disease: are associations explained by triglyceride concentrations. The Caerphilly Prospective Study. Br Heart J 1994, 71:293-296.
14. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 1995, 91:831-837.
15. Liu QZ, Knowler WC, Nelson RG, Saad MF, Charles MA, Liebow IM, Bennett PH, Pettitt DJ: Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians: cross-sectional and prospective analyses. Diabetes 1992, 41:1141-1450.
16. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA: Insulin as a predictor of coronary heart disease: interaction with apo E phenotype: a report from MRFIT. Ann Epidemiol 1994, 4:40-45.
17. Rewers M, Shetterly SM, Baxter J, Hamman RF: Insulin and cardiovascular disease in Hispanics and non-Hispanic whites (NHW): the San Luis Valley Diabetes Study [abstract]. Circulation 1992, 85:865.
18. Ferrara A, Barett-Connor E, Edelstein SL: Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984 to 1991. Am J Epidemiol 1994, 140:857-869.
19. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957. This most recent epidemiologic study provides evidence that insulin is an independent risk factor for CAD.
20. McKeigue P, Davey G: Associations between insulin levels and cardiovascular disease are confounded by comorbidity. Diabetes Care 1995, 18:1294-1298.
21. Savage P, Saad M: Insulin and atherosclerosis: villain, accomplice, or innocent bystander? Br Heart J 1993, 69:473-475.
22. Modan M, Or J, Karasik A, Drory Y, Fuchs Z, Lusdy A, Chetrit A, Halkin H: Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation 1991, 84:1165-1175.
23. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ, Jr, Porte D, Jr: Insulin treatment endogenous, insulin concentration, and ECG abnormalities in diabetic Pima Indians: cross-sectional and prospective analysis. Diabetes 1992, 41:1141-1150.
24. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year morality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
25. Agewell S, Fagerbern B, Attwell S, Wendelhag I, Urbannavisius V, Wikstrand J: Carotid artery intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995, 26:956-960.
26. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R, for the IRAS Investigators: insulin sensitivity and atherosclerosis. Circulation 1996, 93:1809-1817. Data from this investigation provide the first evidence that insulin resistance is associated with CAD.
27. Rewers K, D'Agostino R, Burke G, Zaccaro D, Selby J, Savage P, the Insulin Resistance Atherosclerosis Study (IRAS): Coronary artery disease is associated with low insulin sensitivity independent of insulin levels and cardiovascular risk factors [abstract]. Diabetes 1996, 52:185.
28. Saad MF, Lillioja S, Nyomba BL, Castillo C, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV, Bogardus C: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991, 324:733-739.
29. Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990, 39:167-674.
30. Banerji MA, Lebovitz HE: Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes 1989, 38:784-792.
31. Haffner SM, D'Agostino R, Saad W, Rewers M, Mykkanen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RN: Increased insulin resistance and insulin secretion in non-diabetic African Americans and Hispanics compared to non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes 1986, in press.
32. White MM, Zamudio S, Stevens T, Tyler R, Lindenfeld J, Leslie K, Moore LG: Estrogen, progesterone, and vascular reactivity: potential cellular mechanism. Endocrine Rev 1995, 16:739-751.
33. Fontbonne A: Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994, 3:953-955.
34. Reaven GM Chen Y-DI: Insulin resistance, its consequences, and coronary heart disease: must we choose one culprit? Circulation 1996, 93:1780-1783. This editorial response to the paper by Howard et al. (Circulation 1996, 93:1809-1817) suggests both insulin and insulin resistance contribute to CAD.
35. Ross R: Cell biology of atherosclerosis. Ann Rev Physiol 1995, 57:791-804.
36. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993, 269:3015-3023.
37. Chobanian AV: Corcoran lecture: Adaptive and maladaptive responses of the arterial wall to hypertension. Hyptertension 1990, 15:666-674.
38. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y, Heynen G: Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991, 91:589-596.
39. Haffner SM, Ferrannini E, Hazuda HP, Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals: the San Antonio Heart Study. Am J Epidemiol 1992, 41:715-722.
40. DeFronco RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975, 55:845-855.
41. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87:2246-2252.
42. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989, 321:580-585.
43. Buchanan T, Raffel L, Cantor R, Hodis R Lee D, Deuattro V, Esparrago J, Laurel C, Xiang A, Rotter J, Hsueh WA: Factors associated with salt sensitivity in Latino families [abstract]. Hypertension 1995, 26:454.
44. Julius S: Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993, 21:886-893.
45. Carretta R, Fabris B, Fischetti F, Costantini M, DeBiasi F, Muiesan S, Bardelli M, Vran F, Campanacci L: Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion. J Hypertens 1992, suppl 7:S196-S197.
46. Sheih SM, Sheu WHH, Shen DC, Fuh MMT, Chen YDI, Reaven GM: Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992, 5:827-831.
47. Buchanan TA, Meehan WP, Jeng YY, Yang TM, Chan JL, Nadler JL, Scott J, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995, 96:354-360.
48. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr, O'Grady HK, Davis HE: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993, 328:1220-1225.
49. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to melondialdehyde-lysine in serum. Atherosclerosis Throm 1994, 14:605-616.
50. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657-671.
51. Shih DM, Gu L, Hama S, Xia YR, Vavab M, Fogelman AM, Lusis AJ: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in mouse model. J Clin Invest 1996, 97:1630-1639.
52. Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995, 95:1353-1362.
53. Krishnamurti C, Alving BM: Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thrombosis Hemost 1992, 18:67-80.
54. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I: Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994, 72:44-53.
55. Tamaroglio TA, Lo CS: Regulation of fibronectin by insulin-like growth factor-1 in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells. Exp Cell Res 1994, 21:338-346.
56. Dawson SJ, Hamsten A, Wiman B, Henney AM, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromber 1991, 11:183-190.
57. Eriksson P, Kallin B, VanTHooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92:1851-1855.
58. Ridray S, Heudes D, Michel O, Penicaud L, Ktorza A: Increased SMC proliferation after endothelial injury in hyperinsulinemia obese Zucker rats. Am J Physiol 1994, 267:H1976-1983.
59. Faxon DP, Kip KE, Currier JW, Yeh W, Detre K: Diabetics have significantly poorer eight year outcome after angioplasty [abstract]. Circulation 1995, 97:176.
60. Rabinowitz D, Zierler KL: Forearm metabolism and its response to intra-arterial insulin. J Biol Chem 1990, 264:18051-18054.
61. Creager MS, Liang CS, Coffman JD: Beta adrenergic mediated vasodilator response to insulin in the human forearm. J Pharmacol Exp Ther 1985, 235:709-714.
62. Baron AD: Hemodynamic actions of insulin. Am J Physiol 1994, 267:E187-202.
63. Wu HY, Jeng YY, Yue CJ, Chyu KY, Hsueh WA, Chan TM: Endothelial dependent vascular effects of insulin and insulin-like growth factor-1 in the perfused rat mesenteric artery and aortic ring. Diabetes 1994, 43:1027-1031.
64. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilitation is nitric oxide dependent. J Clin Invest 1994, 94:1172-1179.
65. Meehan WP, Buchanan TA, Hsueh WA: Chronic administration infusion elevates blood pressure in rats. Hypertension 1994, 23:1012-1017.
66. Hall JE, Brands NM, Kivlighn SD, Mizelle HL, Hilderbrandt A, Gaillard CA: Chronic hyperinsulinemia and blood pressure: interaction with catecholamines? Hypertension 1990, 15:519-527.
67. Sawicki PT, Heinemann L, Starke A, Berger M: Hyperinsulinaemia is not linked with blood pressure evaluation in patients with insulinoma. Diabetologia 1992, 35:649-652.
68. Tedde R, Sechi LA, Marigliano A, Pala A, Scano L: Antihypertensive effect of insulin reduction in diabetic-hypertensive patients. Am J Hypertens 1989, 2:163-170.
69. Randeree HA, Omar MAK, Motala AA, Seedat MA: Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992, 15:1258-1263.
70. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Gray A, Coussens L, Liao VC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985, 313:756-761.
71. White MF, Khan CR: The insulin signaling system. J Biol Chem 1994, 269:1-4.
72. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG, Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signaling. Nature 1995, 377:173-177.
73. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B, Johnson RS, Kahn CR: Alternative pathway of insulin signaling in mice with targeted description of the IRS-1 gene. Nature 1994, 372:186-190.
74. Hotamisligol GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor-obesity diabetes central role of tumor necrosis factor alpha. J Clin Invest 1994, 94:1543-1549.
75. Bottaro DP, Bonner-Weir S, King GL: Insulin receptor recycling in vascular endothelial cells: regulation by insulin and phorbol ester. J Biol Chem 1989, 264:5916-5923.
76. Banskota NK, taub R, Zellner K, King GL: Insulin, insulin-like growth factor 1 and platelet derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 1989, 89:1182-1190.
77. Law RE, Woerner PM, XI X-P, Graf K, Coats W, Faxon D, Hsueh WA: Troglitazone (TRO) inhibits vascular smooth muscle cell (VSMC) growth and intimai hyperplasia [abstract]. American Diabetes Association; 1996.
78. Anderson PW, Zhang XY, Tian J, Crreale JM, Xi X-P, Yang D, Graf K, Law RE, Hsueh WA: Angiotensin II are additive in stimulating TGF-β1 and matrix mRNAs in mesangial cells. Kidney Int 1996, in press.
79. Kwok CF, Goldstein BJ, Muller WD, Lee TS, Kahn CR, King GL: Identification of persistent defects in insulin receptor structure and function in capillary endothelial cells from diabetic rats. J Clin Invest 1989, 83:127-136.